Activation of RhoA involves the conversion of GDP-bound RhoA to GTP-bound RhoA by guanine nucleotide exchange factors. The relative abundance of activated RhoA can also be modulated by GTPase-activating proteins and guanine nucleotide dissociation inhibitors. 8 Once active, RhoA translocates to the cell membrane to activate ROCK.
ROCK has diverse effects depending on the cell type. In vascular muscle, ROCK serves as an important regulator of contraction. 8 Activation of ROCK inhibits myosin light chain phosphatase, thus preventing dephosphorylation of myosin and a maintenance or increase in contractile force. This effect on contractile force is not dependent on increases in intracellular calcium. Although ROCK has also been shown to function in endothelium, much less is known about the role of ROCK enzymes in regulating endothelial function during health and disease. One effect of ROCK is the downregulation of nitric oxide (NO) production via inhibitory effects on endothelial NO synthase (eNOS). 9 Brain is one of the end -organs most affected by hypertension. Deleterious effects of hypertension include impaired vasodilation, augmented vasoconstriction, and blood-brain barrier dysfunction. 10 Hypertension is a major risk factor for large and small vessel disease and stroke. [11] [12] [13] ROCK has emerged as a key contributor to regulation of vessel function, Abstract-Rho kinase (ROCK) has been implicated in physiological and pathophysiological processes, including regulation of vascular function. ROCK signaling is thought to be a critical contributor to cardiovascular disease, including hypertension and effects of angiotensin II (Ang II). Two isoforms of ROCK (1 and 2) have been identified and are expressed in vascular cells. In this study, we examined the importance of ROCK2 in relation to vessel function using several models and a novel inhibitor of ROCK2. First, incubation of carotid arteries with the direct RhoA activator CN-03 or Ang II impaired endothelium-dependent relaxation by ≈40% to 50% (P<0.05) without altering endotheliumindependent relaxation. Both CN-03-and Ang II-induced endothelial dysfunction was prevented by Y-27632 (an inhibitor of both ROCK isoforms) or the selective ROCK2 inhibitor SLX-2119. In contrast, SLX-2119 had little effect on contraction of carotid arteries to receptor-mediated agonists (serotonin, phenylephrine, vasopressin, or U46619). Second, in basilar arteries, SLX-2119 inhibited constriction to Ang II by ≈90% without significantly affecting responses to serotonin or KCl. Third, in isolated pressurized brain parenchymal arterioles, SLX-2119 inhibited myogenic tone in a concentration-dependent manner (eg, 1 μmol/L SLX-2119 dilated by 79±4%). Finally, SLX-2119 dilated small pial arterioles in vivo, an effect that was augmented by inhibition of nitric oxide synthase. These findings suggest that ROCK2 has major, but heterogeneous, effects on function of endothelium and vascular muscle. The data support the concept that aberrant ROCK2 signaling may be a key contributor to select aspects of large and small vessel disease, including Ang IIinduced endothelial dysfunction. influencing vascular tone normally and in disease. 6, 7, [14] [15] [16] ROCK activity is associated with increased cardiovascular morbidity and mortality. 17 Basic and clinical evidence have implicated angiotensin II (Ang II) in hypertension and vascular disease, 18, 19 with other studies showing that ROCK is activated by Ang II. 1, [20] [21] [22] Little is known regarding the role of specific ROCK isoforms in the regulation of vascular function. In the present study, we examined the hypothesis that ROCK2 plays an important role in intact vessels under physiological and pathological conditions. Because of its key role in hypertension and vessel disease, we used a model of Ang II-induced vascular dysfunction for portions of the study. As part of our approach, we tested effects of a new, selective ROCK2 inhibitor, SLX-2119 (also known as KD025), 4, 23 on regulation of vascular tone in carotid arteries and resistance vessels in brain. Our findings suggest that ROCK2 plays a key role in endothelial dysfunction produced in response to direct RhoA activation or Ang II. We also found that constriction of cerebral arteries to Ang II and myogenic tone in small parenchymal arterioles is ROCK2-dependent. Overall, these findings support the concept that ROCK2 is a key ROCK isoform in relation to regulation of carotid and cerebrovascular function.
Materials and Methods

Experimental Animals
The protocols used were approved by the University of Iowa Animal Care and Use Committee. We studied male C57Bl6/J mice. All mice were fed standard chow and water ad libitum and studied at 4 to 6 months of age. Care of mice met the standards set forth by the National Institutes of Health for the care and use of experimental animals. Details regarding the experimental procedures are presented in the online-only Data Supplement. Briefly, 4 different segments of the vasculature were used to examine the role of ROCK in various aspects of vascular function. We took advantage of specific features in each vessel type to address specific questions (endothelial function in carotid arteries, myogenic tone in brain parenchymal arterioles, etc).
Statistical Analysis
All data are expressed as mean±SE. Data were evaluated using 1-or 2-way analysis of variance (ANOVA) followed by Tukey post hoc test (for 1-way ANOVA), as appropriate. Statistical significance was accepted at P<0.05.
Results
Direct Activation of RhoA Impairs Endothelial Function in Carotid Arteries in a ROCK2-Dependent Manner
Incubation of arteries with the direct RhoA activator elicited concentration-dependent effects. At 1 μg/mL, CN-03 moderately impaired relaxation to acetylcholine ( Figure 1A ). In contrast, incubation with CN-03 at 2.5 or 5 μg/mL greatly impaired endothelium-dependent relaxation to acetylcholine ( Figure 1A ). Endothelium-independent relaxation to nitroprusside was not affected by CN-03 at any concentration ( Figure 1B ), suggesting that effects were selective for endothelial cells. In most groups, contraction of carotid arteries to U46619 was not significantly affected by incubation with CN-03 (data not shown). Because we obtained a similar degree of endothelial dysfunction with 2.5 or 5 μg/mL CN-03, we used the 2.5 μg/mL concentration in subsequent experiments.
Impaired endothelium-dependent relaxation induced by CN-03 was reversed by Y-27632 (3 μmol/L; Figure 2A ). We next sought to determine which ROCK isoform was being activated by CN-03. The ROCK2 inhibitor SLX-2119 (1 μmol/L) also significantly improved endothelium-dependent responses after CN-03 treatment ( Figure 2C ). In contrast, treatment with Y-27632 or SLX-2119 did not affect responses in vehicletreated groups (Figure 2A and 2C ). In the majority of groups, CN-03 alone or in combination with Y-27632 or SLX-2119 had no effect on relaxation to nitroprusside ( Figure 2B and 2D). We did observe a small shift in the response to submaximal concentrations of nitroprusside with CN-03+Y-27632 versus vehicle only ( Figure 2B ). In this group, contraction of carotid arteries to U46619 was somewhat augmented after incubation with 2.5 μg/mL CN-03 ( Figure S1A in the onlineonly Data Supplement).
Ang II Impairs Endothelial Function in Carotid Arteries in a ROCK2-Dependent Manner
Consistent with previous studies, 24 Ang II (10 nmol/L) impaired endothelium-dependent relaxation of carotid arteries by ≈50% ( Figure 3A ). Endothelial function was restored to normal by treatment with Y-27632 ( Figure 3A ). We observed a leftward shift in the concentration-response curve to acetylcholine compared with the vehicle groups with Ang II+Y-27632 treatment ( Figure 3A ). In addition, endothelial function was restored by SLX-2119 treatment ( Figure 3C ). In most groups, relaxation to nitroprusside was not significantly affected by incubation with Ang II or treatment with Y-27632 or SLX-2119 ( Figure 3B and 3D). However, treatment with Ang II+Y-27632 resulted in a small leftward shift in the concentration-response curve to nitroprusside ( Figure 3B ). Contraction of carotid arteries to U46619 was not significantly affected by incubation with Ang II ( Figure S1B ).
Because SLX-2119 improved endothelial function after treatment with Ang II, we tested whether the increased vasorelaxation to acetylcholine was mediated by NO using N G -nitro-L-arginine (L-NNA) in an additional group. We found that the increased response to acetylcholine produced by SLX-2119 (after treatment with Ang II) was prevented by L-NNA ( Figure S2A ). Relaxation of arteries to nitroprusside was similar in these groups ( Figure S2B ).
Contraction of Carotid Arteries to Several Receptor-Mediated Agonists Is Independent of ROCK2
We next tested effects of ROCK2 inhibition on contractile responses to several agonists, including 2 that are inhibited by Y-27632 (serotonin and phenylephrine) in carotid arteries. 25 Contraction of freshly isolated carotid arteries (ie, no incubation with CN-03 or Ang II) to serotonin ( Figure 4A ), phenylephrine ( Figure 4B ), vasopressin ( Figure 4C ), or U46619 ( Figure 4D ) was not significantly affected by SLX-2119 (1 μmol/L). 
ROCK2 Mediates Constriction to Select Agents in Basilar Arteries
We previously found that Y-27632 essentially abolished constriction of basilar arteries to Ang II. 20 SLX-2119 did not affect baseline diameter of basilar arteries (162±4 and 161±4 μm in vehicle-and SLX-2119-treated groups, respectively; n=10). However, constriction to Ang II in basilar arteries was reduced by ≈90% by SLX-2119 (1 μmol/L; Figure 5A ). In contrast, vasoconstriction to serotonin ( Figure 5B) or KCl (50 mmol/L; Figure 5C ) was not significantly affected by SLX-2119. 
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Myogenic Tone Is Dependent on ROCK2 in Parenchymal Arterioles
Generation of myogenic tone by cerebral arteries and arterioles is a major element of mechanisms that underlie autoregulation of cerebral blood flow. Parenchymal arterioles develop substantial myogenic tone [26] [27] [28] and are key contributors to overall cerebral vascular resistance. 29 In the current study, parenchymal arterioles generated spontaneous tone once pressurized (37.1±3.0% of maximum diameter; n=10 arterioles) to a baseline diameter of 17±2 μm (active diameter). Subsequent application of NS-309 caused marked dilation of parenchymal arterioles ( Figure 6A ; n=8 arterioles). The observation that NS-309, an activator of small-and intermediate-conductance Ca 2+ -activated K + channels, produced robust vasodilation suggested that endothelial function was intact in these arterioles. The cumulative addition of SLX-2119 (0.1 nmol/L-10 μmol/L) dilated parenchymal arterioles ( Figure 6B ). At 1 μmol/L, a concentration where SLX-2119 is highly selective for ROCK2 versus ROCK1, 4 SLX-2119 dilated parenchymal arterioles by 78.9±4.0%. In contrast, addition of vehicle (DMSO) had minimal effect on myogenic tone ( Figure 6B ). In a separate group of vessels studied under the same conditions, Y-27632 dilated parenchymal arterioles to a comparable degree as SLX-2119, with a maximum response of 89.8±2.3% (10 μmol/L; n=6).
Diameter of parenchymal arterioles under passive, calciumfree conditions was 26±3 μm.
ROCK2 Influences Resting Diameter of Pial Arterioles In Vivo
In pial arterioles in vivo, SLX-2119 produced moderate dilation ( Figure 6C ). Local treatment with the NOS inhibitor L-NNA did not alter baseline diameter (34±3 μm before L-NNA versus 34±3 μm after 30 minutes L-NNA incubation), but the magnitude of the response to SLX-2119 was significantly augmented ( Figure 6C ).
Discussion
In the present study, we obtained evidence supporting the concept that ROCK2 plays a key role in regulating the function of both large arteries as well as the smallest arterioles. We made several novel findings. First, direct activation of RhoA using CN-03 selectively impairs endothelial function in carotid arteries via a ROCK2-dependent mechanism. Second, Ang II-induced endothelial dysfunction in carotid arteries is also dependent on ROCK2. The ROCK2 inhibitor restored the NO component of this response. Third, contraction of carotid arteries to phenylephrine, serotonin, vasopressin, and U46619 are largely independent of ROCK2. Fourth, constriction of basilar arteries to Ang II, but not serotonin or KCl, requires normal activity of ROCK2. Fifth, myogenic tone in brain parenchymal arterioles is highly dependent on ROCK2. Finally, the influence of ROCK2 on arteriolar microvascular tone in vivo is modulated by NO. These novel findings suggest that ROCK2 is a major regulator of vascular tone in muscular arteries, as well as resistance vessels in brain.
Experimental Approaches to Study ROCK
The majority of findings dealing with the impact of ROCK in the vasculature are based on studies that used pharmacological inhibitors. In relation to selectivity, 2 of the most commonly used inhibitors of ROCK (Y-27632 and fasudil) can also inhibit other enzymes, with fasudil being the least selective of the two. 30, 31 Of importance for the present study, Y-27632 and fasudil have similar inhibitory constants (K i ) for ROCK1 and ROCK2. 4 In contrast, SLX-2119 is highly selective for ROCK2 compared with ROCK1 (K i : >10 000 nmol/L for ROCK1 versus 41 nmol/L for ROCK2). 4 In contrast to pharmacological inhibitors, only a small number of studies have used genetic manipulation of ROCK to study its functional effects. The lack of available genetic models has contributed to our limited understanding of the relative contribution of specific ROCK isoforms in vascular disease. More than 90% of mice fully deficient in either ROCK isoform (Rock1 −/− and Rock2 −/− ) die in utero or early in the postnatal period. 9 Therefore, studies using such mice need to be interpreted with caution because surviving animals may have compensatory effects of the remaining ROCK isoform. 9 For such reasons, a few studies have used heterozygous Rock1 +/− and Rock2 +/− mice. Using such mice, for example, diabetes mellitus-induced endothelial dysfunction in aorta was primarily mediated by ROCK1, with a smaller role for ROCK2. 3 Neointima formation after carotid artery ligation was reduced in Rock1 +/− mice. 32, 33 In cell culture studies, gene silencing techniques suggested that ROCK1 contributes to stiffening of endothelial cells and increased vascular permeability. 34 Furthermore, in aortic vascular muscle in culture, siRNA against ROCK2, but not ROCK1, reduced contraction to the phospholipid lysophosphatidic acid. 35 Effects of other vasoconstrictor stimuli were not tested. Although such efforts have begun to define roles for different ROCK isoforms, the limited data to date in intact blood vessels make it difficult to predict which isoform would be of more importance in regulating function in endothelium versus vascular muscle.
An important gap in our understanding is that previous work has not provided insight into the impact of specific ROCK isoforms in resistance vessels. In brain, both arteries and arterioles are resistance vessels. For example, surface arteries and arterioles contribute ≈50% of total vascular resistance. 18, 29 Parenchymal arterioles are the major resistance vessel within the brain itself. 18, 29 Thus, dysfunction at any of these levels can have a significant impact on local vascular resistance and thus blood flow. In some cases, such vascular changes have longterm consequences for neurological function. 
Influence of ROCK on Endothelial Function
The function of ROCK in the vasculature has been studied most widely in relation to its role in vascular muscle, where it regulates contraction. Increases in calcium sensitivity are achieved via the ROCK-mediated inhibition of myosin light chain phosphatase. Inhibition of myosin light chain phosphatase activity decreases the dephosphorylation of myosin light chain. Thus, even in the absence of any further rise in intracellular calcium, contractile force can be maintained or increased because of the lack of phosphatase activity by myosin light chain phosphatase.
Much less is known regarding the function of ROCK in endothelium. One area that has received some attention relates to how ROCK affects eNOS. Such effects may occur via several mechanisms. ROCK can impair eNOS activity via a reduction in the phosphorylation of a key residue, serine 1177. 36 In addition, ROCK can directly phosphorylate eNOS at threonine 495, which inhibits eNOS activity. 36, 37 The balance between phosphorylation at serine 1177 and threonine 495 determines the activity of eNOS. Other studies suggest that ROCK inhibition increases eNOS expression via increased eNOS mRNA stability. 5, 38 Either alone or in combination, these effects of ROCK on eNOS expression and activity would be predicted to substantially alter NO bioavailability.
In the present study, we used 2 agents to induce endothelial dysfunction, CN-03 and Ang II. Although beneficial effects of ROCK inhibition on vascular function are known, it was unclear whether direct activation of this pathway is sufficient to cause endothelial dysfunction. The direct RhoA activator, CN-03, mimics the effect of cytotoxic necrotizing factor-1 from Escherichia coli, de-amidating the glutamine at position 63 to glutamate. 39 CN-03 has been used mostly in cell culture, so data on effects in intact vascular tissue are limited. We 6 and others 40 found that CN-03 increases myogenic tone in cerebral arteries and arterioles in a ROCKdependent manner.
We initially tested whether direct activation of RhoA, and therefore ROCK, with CN-03 was sufficient to impair endothelial function. CN-03 produced concentration-dependent impairment of endothelium-dependent relaxation, but did not inhibit endothelium-independent relaxation. Impaired relaxation to acetylcholine after incubation with CN-03 was reversed by both Y-27632 and the ROCK2 inhibitor SLX-2119. The finding that both inhibitors restored endotheliumdependent responses suggests that ROCK2 is the isoform that is primarily responsible for the dysfunction. These findings show for the first time that treatment of arteries with CN-03 is a novel approach to induce endothelial dysfunction specifically via activation of ROCK.
We next tested whether ROCK2 also mediated Ang IIinduced endothelial dysfunction. As previously reported, 24 incubation with Ang II induced endothelial dysfunction in wild-type mice. Endothelial dysfunction in this model, which examines direct effects of Ang II on the vessel wall, is dependent on interacting immune-and oxidative stress-dependent mechanisms. 18 The novel finding of the present study is that ROCK2 plays an essential role in Ang II-induced endothelial dysfunction. There are several ways such interactions might occur, including activation of RhoA or ROCK by reactive oxygen species.
We observed a leftward shift in the concentration response curves to acetylcholine and nitroprusside in the group treated with Ang II and Y-27632. The physiological relevance of this finding is unclear because Y-27632 did not have similar effects in vessels not treated with Ang II or treated with CN-03. One potential explanation is that because Y-27632 would also inhibit ROCK1, its use may unmask an influence of ROCK1 in modulating endothelial function. This possibility would need further investigation.
The finding that a ROCK2 inhibitor improves endothelium-dependent (NO-mediated) relaxation in arteries after CN-03 or Ang II treatment suggests a key role for this isoform in endothelium. These findings are consistent with previous studies where fasudil improved endothelial function in an Ang II-dependent model of hypertension.
1 Like SLX-2119 in the current study, fasudil restored the NO component of the response in that study, 1 consistent with the concept that increased ROCK activity impairs endothelial function via effects on production of NO. 1 This negative interaction between ROCK2 and NO during vascular disease is consistent with the finding that ROCK activity correlates positively with the incidence of cerebrovascular events.
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Role of ROCK in Receptor-Mediated Vasoconstriction
Although previous studies revealed that contraction of carotid arteries to serotonin and phenylephrine are inhibited by Y-27632, 25 inhibition of ROCK2 did not significantly impair contraction of the same arteries to phenylephrine, serotonin, vasopressin, or U46619. Such findings suggest that ROCK1 may be more important as a mediator of agonist-induced contraction in large muscular arteries. Consistent with this concept, contraction to phenylephrine is reduced in aorta from Rock1 +/− mice, whereas it is not significantly altered in Rock2 +/− mice. 3 Collectively, such findings suggest a heterogeneous contribution of ROCK isoforms to various agonistinduced vasoconstrictor responses.
Ang II constricts many vessels, including cerebral arteries, via activation of AT1 receptors. 20 Previous work has shown that Ang II constricts basilar arteries via activation of ROCK, as the response was abolished by Y-27632. 20 In the present study, we extend those findings by examining effects of ROCK2 inhibition on vasoconstriction to Ang II. Our results suggest that vasoconstrictor effects of Ang II in cerebral arteries are predominantly ROCK2-dependent. Consistent with findings in the carotid artery, SLX-2119 did not have a significant effect on constriction of the basilar artery to serotonin.
Regulation of Myogenic Tone by ROCK
Myogenic tone of vascular muscle in resistance vessels is a key contributor to the autoregulatory response. Autoregulation is the collective process by which blood flow is kept relatively constant over a range of perfusion pressures. 41 Numerous molecules and pathways have been suggested to contribute to myogenic tone and myogenic responses (for review see HillEubanks et al 42 ). However, the precise molecular details by which cerebral and systemic arteries and arterioles generate myogenic tone remains unsettled. We 6 and others 16, 43 have provided evidence that ROCK is a key determinant of myogenic tone in middle and posterior cerebral arteries. Furthermore, ROCK inhibitors with no isoform selectivity (Y-27632 and H-1152) cause marked dilation of parenchymal arterioles during health and disease (present work and previous studies 26, 40, 44 ), highlighting the importance of ROCK in regulating myogenic tone at multiple levels within the cerebral vasculature. In the current study, we extend those findings by obtaining evidence that ROCK2 specifically is a major regulator of myogenic tone in brain parenchymal arterioles. Parenchymal arterioles connect larger pial arteries and arterioles to the underlying capillary network. Because parenchymal arterioles are immediately upstream of capillaries, they are a key regulators of local cerebral blood flow. 45 These arterioles have been described as a bottleneck in delivering nutrients to the brain parenchyma, and as such, disruption of parenchymal arteriolar function has dramatic effects on downstream perfusion. 46 Although emerging evidence indicates that this segment of the vasculature is particularly affected by small vessel disease, 11, 12 there is still relatively little known regarding regulation of function in this important portion of the vasculature. Our findings suggest that myogenic tone in parenchymal arterioles is almost completely dependent on activity of ROCK2.
Finally, we examined the influence of ROCK2 on pial microvascular diameter in vivo. Previous work using Y-27632 suggested that ROCK influences arteriolar tone under normal conditions. 15 The findings of the present study suggest that ROCK2 is the isoform that mediates this effect. Consistent with previous work with Y-27632, 15 we found that the NOS inhibitor L-NNA augmented vasodilator responses to SLX-2119. It is unlikely that this effect of L-NNA is nonspecific because we and others have found previously that vasodilation to papaverine, low concentrations of potassium, adenosine, and norepinephrine are not augmented by L-NNA (or N G -nitro-L-arginine methyl ester [L-NAME]). [47] [48] [49] [50] Overall, these new findings suggest that in cerebral arterioles from normal animals, basal NO inhibits the influence of ROCK2 on vessel tone. Such an effect may serve as an important protective mechanism to limit the generation of excessive levels of arteriolar tone.
Links Between Ang II and ROCK2
The present findings have implications for hypertension and vascular disease. Ang II has been widely implicated in various forms of hypertension, and the renin-angiotensin system is a major therapeutic target. 19 Two of the key vascular effects of Ang II are endothelial dysfunction and vasoconstriction, both with significant physiological consequences. Endothelial dysfunction plays a fundamental role in the onset and progression of vascular disease. 18 In addition to hypertension, Ang II promotes endothelial abnormalities and atherosclerosis in the presence of other cardiovascular risk factors, including diabetes mellitus and aging. 18 Considering this broad impact, the finding that ROCK2 inhibition restored endothelial function in a model of Ang II-induced vascular disease suggests that ROCK2 may be an important therapeutic target.
Vasoconstrictor effects of Ang II have several potential consequences. Increases in vascular tone can contribute to global or local changes in vascular resistance, as well as producing hypoperfusion, which in brain may contribute to the cognitive effects of hypertension. Finally, sustained increases in vascular tone may be involved in initiating structural changes in the vasculature known as inward remodeling. The finding that SLX-2119 inhibited the majority of constriction of cerebral arteries to Ang II is further evidence that ROCK2 may be involved in more than one component of the disease process, implying that targeting ROCK2 may have broad therapeutic potential.
In summary, the present study suggests that ROCK2 contributes to several aspects of vascular function under normal conditions and in 2 models of vascular disease. Activation of RhoA, and as a consequence ROCK, is sufficient to cause profound endothelial dysfunction. We identify a novel, highly targeted method to impair endothelial function using CN-03. Our data suggest that ROCK2 contributes to both CN-03 and Ang II-induced endothelial dysfunction. In addition, key roles for ROCK2 as a mediator of vasoconstriction to Ang II and myogenic tone in small parenchymal arterioles were revealed. In contrast, ROCK2 seems to play a much smaller role in vasoconstriction to several receptor-mediated agonists. 51 although clinical trails with other inhibitors and diseases are ongoing. The recent development of more selective inhibitors like SLX-2119, in combination with better insight into the impact of specific ROCK isoforms at the cellular and molecular level, should facilitate this translational effort. SLX-2119 is safe, well tolerated, and orally active in humans and mice, 4, 23 making it or related approaches that target ROCK2 a good candidate for therapeutic use. The current studies highlight the potential benefit of ROCK2 inhibition in models of disease, as well new insight into the functional importance of ROCK2 in resistance vessels. Further studies in this area may facilitate approaches that could be used to prevent, delay, and possibly reverse key elements in the progression of large or small vessel disease.
• These findings support the concept that ROCK2 is a key ROCK isoform in relation to regulation of carotid and cerebrovascular function. These are the first functional data related to the impact of ROCK2 in resistance vessels.
What Is Relevant?
• Little is known regarding the role of specific ROCK isoforms in the regulation of vascular function.
• Considering the importance of Rho kinase in vascular cells, these findings have implications for mechanisms that regulate brain perfusion, endothelial function, and the pathogenesis of large and small vessel disease.
Summary
This study provides new insight into the impact of ROCK2 on several aspects of vascular function under normal conditions and in 2 models of vascular disease. Activation of ROCK2 was sufficient to cause profound endothelial dysfunction. We describe a new approach to study endothelial function using CN-03, obtaining evidence that ROCK2 contributes to both CN-03 and angiotensin IIinduced endothelial dysfunction. In addition, key roles for ROCK2 in vasoconstrictor responses to angiotensin II and myogenic tone in small parenchymal arterioles were revealed. The studies highlight the potential benefit of ROCK2 inhibition in models of disease as well new insight into the functional importance of ROCK2 in resistance vessels. 
Novelty and Significance
SUPPLEMENTARY MATERIALS AND METHODS
Carotid artery function. Mice were euthanized with pentobarbital (100 mg/kg ip), carotid arteries were isolated, cleared of connective tissue and cut into rings (2-3 mm) as described in detail previously 1 . We used two approaches to induce endothelial dysfunction. First, arteries were incubated with vehicle (0.9% saline) or the direct RhoA activator CN-03 (1, 2.5 or 5 μg/ml) in DMEM for 22 hours at 37°C (gassed with 95% O2, 5% CO2). CN-03 converts the glutamine residue at position 63 on RhoA to glutamate, making RhoA constitutively active 2 . Second, in separate experiments, arteries were incubated with vehicle (0.9% saline) or Ang II (10 nmol/L) in DMEM for 22 hr at 37°C (gassed with 95% O2, 5% CO2) as previously described 3 .
Following incubation, arteries were suspended in organ baths. Resting tension was increased in a stepwise manner to a final tension of 0.25 g 1 . Vessels were sub-maximally contracted (50-60% of maximum) with the thromboxane A2 mimetic U46619. Acetylcholine was used to test endothelium-dependent relaxation and nitroprusside was used to test endothelium-independent relaxation. We have shown previously that responses to acetylcholine are mediated by eNOS in carotid arteries 1, 4 . Y-27632, a Rho kinase inhibitor that does not distinguish between ROCK isoforms, or the ROCK2 selective inhibitor SLX-2119 was used to examine mechanisms of vascular dysfunction. In an additional group of mice, we used the NOS inhibitor N G -nitro-L-arginine (L-NNA, 100 μmol/L) to determine whether SLX-2119 ameliorated Ang II-induced endothelial dysfunction via effects on NOS.
We previously found that contraction of normal carotid arteries to serotonin and phenylephrine were substantially inhibited by Y-27632 5 . We pursued those findings by testing effects of SLX-2119 on contraction to the same receptor-mediated agonists along with arginine vasopressin and U46619.
Cerebral vascular function ex vivo. Mice were euthanized as described above, followed by removal of the brain. Basilar arteries were isolated, cannulated, and pressurized to 60 mmHg in warmed (37°C) Krebsbicarbonate solution as described 6, 7 . Following a 30 min equilibration period, viability was tested by exposure to 50 mmol/L KCl. Cumulative concentrationresponse curves to Ang II or serotonin were performed in the absence and presence of the ROCK2 inhibitor SLX-2119. To determine whether SLX-2119 non-selectively affected vessel contractility, we repeated KCl responses in the presence of SLX-2119.
To examine the influence of ROCK2 on myogenic tone, we studied brain parenchymal arterioles as described in detail 8, 9 . Brains were removed and placed in ice-cold MOPS buffered saline solution (composition in mmol/L: 145 NaCl, 5 KCl, 1 KH2PO4, 1 MgSO4, 2.5 CaCl2, 5 D-glucose, 3 MOPS, 0.02 EDTA, 2 pyruvate, bovine serum albumin [10 mg/mL], pH 7.4 at 4°C). Parenchymal arterioles from the middle cerebral artery territory were isolated, cannulated, pressurized and equilibrated for one hour in warmed (37°C) artificial cerebrospinal fluid (aCSF; composition in mmol/L: 125 NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 4 D-glucose, 2 CaCl2) during which time they developed spontaneous myogenic tone (active vessel diameter). Vessels were pressurized to 40 mmHg as this level approximates their normal intravascular pressure in vivo 10 . Following equilibration, viability of the endothelium was assessed by exposure to the small-and intermediateconductance Ca 2+ activated K + channel activator, NS-309 (1 μmol/L). Following washout, cumulative concentration-response curves to SLX-2119 or vehicle (DMSO) were performed. Typically, two vessels per animal were studied simultaneously (SLX-2119 and vehicle). In some arterioles, effects of Y-27632 were tested. Passive vessel diameters were obtained by superfusion of Ca 2+ free aCSF containing 100 μmol/L nitroprusside and 2 mmol/L EGTA (passive vessel diameter). Myogenic tone was calculated by the following formula: [(Ca 2+ -free diameter) -(Ca 2+ -containing diameter following equilibration)] / (Ca 2+ -free diameter) × 100.
Cerebral vascular function in vivo.
For studies of small cerebral arterioles in vivo, mice were anesthetized with pentobarbital (75-90 mg/kg IP), supplemented at ~20 mg/kg per hour. Animals were ventilated mechanically and a cranial window was prepared over the somatosensory cortex as previously described 7 . Arterial blood pressure and blood gases were monitored during the experiment. Using Y-27632, we previously found that basal production of NO inhibits the influence of Rho kinase on cerebral arteriolar tone in vivo 11 . To explore this concept in relation to ROCK2, changes in arteriolar diameter were measured in response to SLX-2119 in the absence or presence of L-NNA. L-NNA (100 μmol/L) was suffused topically for 30 min prior to commencing the second concentration-response curve to SLX-2119.
Drugs. CN-03 and SLX-2119 were purchased from Cytoskeleton Inc. (Denver, CO) and ApexBio (Houston, TX), respectively. NS-309 and Y-27632 were purchased from Tocris (Minneapolis, MN). All other chemicals were obtained from Sigma (St Louis, MO). SLX-2119 was dissolved in 100% dimethyl sulfoxide (DMSO) at a concentration of 1 mmol/L and subsequently diluted in saline such that the final concentration of DMSO was ≤0.1% (studies of carotid and cerebral arteries) or ≤1% (studies of cerebral arterioles). NS-309 was dissolved in 100% DMSO at a concentration of 10 mmol/L and subsequently diluted in saline such that the final concentration of DMSO was ≤0.01%. All other drugs dissolved and diluted in saline. 
